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Abstract
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL)
in adults, data on safety and efﬁcacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/
refractory ALL treated in the compassionate use program. In this heavily pretreated cohort, complete remission was achieved
in 67% of patients with overt marrow disease. The majority (71%) of responders were negative for minimal residual disease.
Responses were observed irrespective of cytogenetic subtype or number or type of prior treatment regimens. InO was well-
tolerated; grade 3 hepatic transaminitis or hyperbilirubinemia were noted in 6 (12%) and grade 3/4 infections in 11 (22%)
patients. No patient developed sinusoidal obstruction syndrome (SOS) during InO therapy; however, 11 of 21 (52%) patients
who underwent hematopoietic stem cell transplantation (HSCT) following InO developed SOS. Downregulation of surface
CD22 was detected as a possible escape mechanism in three patients who developed a subsequent relapse after InO. We
conclude that InO is a well-tolerated, effective therapy for children with relapsed ALL and prospective studies are warranted.
Identiﬁcation of risk factors for developing post-HSCT SOS and strategies to mitigate this risk are ongoing.
Introduction
Despite tremendous progress made in the therapy for
childhood acute lymphoblastic leukemia (ALL), approxi-
mately 10–15% of children relapse [1]. Intensive salvage
regimens result in suboptimal 2-year disease-free survival
rates of only 41 and 13% for children in second and third
remission respectively [2]. Furthermore, these outcomes
have not improved signiﬁcantly in the past two decades [3].
Progressive leukemia remains one of the leading causes of
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disease-related death in children and novel therapeutic
options are urgently needed.
Inotuzumab ozogamicin (InO) is a CD22-directed huma-
nized monoclonal antibody conjugated to the potent cyto-
toxin calicheamicin [4]. CD22 is widely expressed on B-
ALL blasts and is rapidly internalized upon antibody bind-
ing, making it an excellent target for immune-targeted che-
motherapy in B-ALL [5, 6]. In studies of adult patients with
relapsed/refractory B-ALL, InO has demonstrated impressive
single agent activity [4, 7]. The overall response rate in a
phase II study of 49 patients was 58% [8]. Of patients who
responded, 72% achieved minimal residual disease (MRD)
negativity (<0.01%). A fractionated dosing regimen was
associated with less hepatotoxicity than a single dose regi-
men and was studied in a large randomized phase 3 study
(INO-VATE) wherein patients were randomized to receive
InO vs. standard chemotherapy for ﬁrst or second salvage
[9]. The complete response (CR) rate for the InO group was
80.7% compared to 33.3% for the standard of care group
(p < 0.0001). MRD-negativity was achieved at a higher rate
in the InO arm (78.4 vs. 28.1%, p < 0.0001) and duration of
remission was greater. Based on the results of this study, InO
was granted Breakthrough Therapy designation by the U.S.
Food and Drug Administration (FDA) in October 2015, and
was approved by the FDA in August 2017 for the treatment
of relapsed/refractory B-ALL in adults [10].
InO is relatively well tolerated in adult patients. How-
ever, similar to the experience with gemtuzumab ozoga-
micin, an anti-CD33 antibody drug conjugate also linked to
calicheamicin, an increased incidence of sinusoidal
obstruction syndrome (SOS), previously known as veno-
occlusive disease, has been observed with InO [11, 12].
InO-associated SOS is particularly notable in the post-
hematopoietic stem cell transplant (HSCT) setting. Other
common toxicities observed are thrombocytopenia, neu-
tropenia, fever, liver function abnormalities, and diarrhea
[9]. Several studies in adult patients that combine InO with
conventional chemotherapy in frontline and relapsed ALL
have been recently reported [13, 14].
Leukemic blasts from children with B-ALL strongly
express CD22 [6], but pediatric experience with InO is
extremely limited, with one phase II adult trial having also
enrolled ﬁve children [8, 15]. Three patients received the
single dose regimen, and two received the fractionated dose
regimen. Three of these ﬁve patients achieved a CR and had a
comparable toxicity proﬁle to the adult cohort, including
fever, sepsis and hepatic transaminase elevation. In spite of
remarkable efﬁcacy in relapsed/refractory disease and the
FDA approval of InO in adults, development of this agent in
children has lagged, with the ﬁrst pediatric studies initiated in
2016–2017. In the interim, Pﬁzer provided InO to approxi-
mately 100 children from 2013 to 2016 via a compassionate
use program. In this study, we collected retrospective data
from multiple international pediatric oncology centers that
treated children with InO by compassionate use and per-
formed a detailed review of the activity and toxicity proﬁle of
InO in children with relapsed/refractory ALL. Data from this
study will inform larger prospective pediatric studies and
provide guidance regarding InO therapy and anticipated
toxicity to clinicians awaiting results of pediatric clinical trials.
Subjects and methods
This was a retrospective cohort study of pediatric patients
with relapsed/refractory B-ALL who received InO in the
compassionate use program. Eligibility criteria for this
program included unavailability of satisfactory alternate
therapy, CD22 positivity on leukemic blasts, serum creati-
nine ≤ 1.5×, bilirubin ≤ 2× and AST/ALT ≤ 2.5× upper limit
of normal, absence of severe uncontrolled infection, no
history of prior SOS, and a washout of 14 days from another
investigational agent. Patients/families consented to mon-
itoring of toxicities.
This current study was not linked to Pﬁzer or regulatory
approvals for drug procurement or administration. Partici-
pating pediatric oncology centers obtained separate local
institution review board (IRB) or ethics committee
approvals as applicable, to contribute demographic, treat-
ment, outcome and toxicity data to this study. Participating
physicians and research coordinators reviewed patient
medical records to collect data and sent de-identiﬁed data to
the study team for review and analyses.
Patients were eligible if they were ≤21 years of age at the
time of InO administration and had received a minimum of
one dose of InO. All patients received the now FDA-
approved fractionated dosing schedule of InO. One cycle
consisted of three doses: 0.8 mg/m2 on week 1 followed by
0.5 mg/m2 on weeks 2 and 3. One patient with MRD-only
disease received 0.5 mg/m2/dose for all three doses. In
second and subsequent cycles, assuming CR/CRi during
cycle 1, patients received 0.5 mg/m2/dose on days 1, 8, and
15. Disease response was determined by local institutions at
the completion of each cycle at approximately day 28.
Complete remission (CR) was deﬁned as <5% bone marrow
blasts by morphology, CR with incomplete count recovery
(CRi) as CR with absolute neutrophil count <500/cu.mm or
platelet count <50,000/cu.mm. Partial response was deﬁned
as the reduction of marrow disease burden from >25%
blasts (M3) to 5–25% blasts (M2). MRD was measured
either by ﬂow cytometry or polymerase chain reaction
(PCR) of immunoglobulin gene rearrangements. Toxicities
during and for 30 days post InO therapy were graded per
Common Terminology Criteria for Adverse Events
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(CTCAE) version 4.03. Information from safety reporting
forms originally submitted to the sponsor was also collected
and included in the analyses. Additional clinical informa-
tion was gathered for patients who underwent HSCT after
treatment with InO to capture occurrence and severity of
post-HSCT SOS. Severity of SOS was graded per institu-
tional practice.
Statistical analyses
Analytic endpoints included CR, event-free survival (EFS)
deﬁned as the time from start of treatment to earliest
occurrence of treatment failure, disease relapse, or death
from any cause, and overall survival (OS) deﬁned as the
time from start of treatment to death from any cause. The
latter two endpoints were censored at the time of last
reported follow-up. The data cutoff date was December 31,
2016. Univariable and multivariable logistic regression was
used to examine associations between patient and disease
characteristics and the probability of achieving CR. Uni-
variable and multivariable Cox regression analysis was used
to assess the associations between EFS/OS and patient/
disease characteristics. Estimates of EFS or OS probability
were based on the product limit estimator with Greenwood
standard errors. Reported p values are all two-sided. All
analyses were performed using Stata (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station, TX:
StataCorp LP).
CD22 antigen expression
In a limited number of patients, there was an opportunity to
serially evaluate CD22 expression using methods that have
been previously described [6]. Patients were separately
consented to another IRB-approved prospective study also
targeting CD22 which allowed for screening of their leu-
kemia samples. In this screening process, samples were
available for three patients before and after InO without any
intervening therapy, allowing for assessment of the impact
of InO on CD22 expression.
Table 1 Patient characteristics
Patient characteristics N %
Location North America 30 58.8
Europe 18 35.3
Australia 3 5.9
Age 2–4 years 3 6
5–9 years 13 25
10–17 years 31 61
18–21 years 4 8
Sex Male 30 59
Female 21 41
Down syndrome Yes 4 8
No 47 92
Cytogenetic subtype ETV6-RUNX1 5 10
Hyperdiploid 4 8
Ph-like 4 8
Ph-positive 3 6
Hypodiploid 3 6
TCF3-PBX1 2 4
KMT2A-rearranged 1 2
t(17;19) 1 2
iAMP21 1 2
NOS 19 37
Unknown 8 16
Indication for InO First relapse
(refractory)
10 20
Second relapse 22 43
Third relapse 10 20
Forth relapse 6 12
Fifth relapse 2 4
Primary refractory 1 2
Refractory to preceding regimen Yes 41 80
No 9 18
Unknown 1 2
Number of prior treatment
regimens (excluding HSCT)
2–3 8 16
4–6 28 55
≥7 15 29
Prior HSCT None 29 57
1 18 35
2 3 6
3 1 2
Prior CD19-directed therapy Blinatumomab 22 43
CD19 CAR T-cells 15 29
Both of the above 3 6
None 11 22
Prior CD22-directed therapy Moxetumomab 6 12
CD 22 CAR T-cells 3 6
Both of the above 1 2
InO 1 2
Table 1 (continued)
Patient characteristics N %
None 40 78
Bone marrow status M1, MRD positive 8 16
M2 4 8
M3 38 75
Unknown 1 1
Extramedullary disease Yes 2 4
No 49 96
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Results
Patient characteristics and InO therapy
From the approximately 100 children treated via the com-
passionate access program, we obtained data on 51 patients,
ages 2.2 years to 21.3 years (median 11.5 years) who
received InO from January 2013 to December 2016 at 30
pediatric oncology centers in North America, Europe, and
Australia. All but three patients received InO in 2015 or
2016. Detailed patient characteristics are listed in Table 1.
Four patients had Down syndrome. Patients were either
refractory to primary therapy (N= 1) or in ﬁrst to ﬁfth
relapse, and heavily pretreated (2–9 prior regimens; median
5). All ten patients in ﬁrst relapse had received multiple
salvage regimens, including HSCT in four. The majority of
patients (N= 41, 80%) were refractory to their preceding
regimen. Twenty-two patients (43%) had undergone one or
more prior HSCT, 40 (78%) had received prior CD19-
directed therapy with either CD19 CAR T cells and/or
blinatumomab while 10 (20%) had received prior CD22-
directed therapy with either CD22 CAR T cells and/or
moxetumomab. One patient had received InO on the adult
phase II study a year earlier, achieved CR and subsequently
relapsed after HSCT. At the time of InO administration,
leukemia burden was M3 marrow (>25% blasts) in 38
patients, M2 (5–25% blasts) in 4, M1 ( < 5% blasts) in 8,
and unknown in 1 patient. Of eight patients with M1 mar-
row, all had detectable MRD ranging from 0.05 to 4%. Two
patients had concomitant bulky extramedullary disease
(salivary gland and a skull-based lesion). The median
number of doses of InO received was 5 (range 1–15).
Twenty-three (45%) patients received ≤1 cycle, 19 (37%)
patients received all or part of two cycles, and 9 (18%)
patients received more than two cycles of InO.
Response to InO
Complete responses were reported in 28 of 42 (67%)
patients with overt relapse (M2/M3 marrow): CR in 15
(36%) and CRi in 13 (31%). Three patients had a partial
response (7%) and eight had no response (19%). Three
patients were not evaluable for response as InO was stopped
prior to the completion of cycle 1, i.e. less than three doses.
Of 28 patients in CR/CRi, 20 (71%) achieved MRD nega-
tivity deﬁned as less than 0.01% by ﬂow cytometry or PCR.
The majority of patients who achieved CR/CRi (N= 24,
86%) did so after the ﬁrst cycle of InO. All four patients
with M2 disease burden achieved MRD-negative CR/CRi.
Responses in patients with MRD-positive disease-only (M1
marrow; N= 8) were as follows: four achieved MRD
negativity, MRD decreased by 1–2 logs in two patients,
MRD remained stable in one patient and MRD increased in
one patient. The patient with salivary gland disease attained
CR in the extramedullary site, with stable marrow MRD,
and the patient with a skull-based lesion developed pro-
gressive disease at the extramedullary site (but CRi in the
marrow). A renal chloroma and vertebral mass were inci-
dentally discovered in one additional patient while receiving
InO (unknown if present prior to InO therapy).
No baseline patient or disease characteristic (age, sex,
cytogenetic subtype) was identiﬁed as a signiﬁcant prog-
nostic indicator for response. All three patients with Phila-
delphia chromosome-positive (Ph-positive) ALL attained
CR/CRi, one of whom was MRD-negative. Three of four
patients with Philadelphia chromosome-like (Ph-like) ALL
achieved CR/CRi; one was MRD-negative. Of three
patients with hypodiplod ALL, two were in CR post InO
(both MRD-positive). The single patient with KMT2A
rearrangement in this cohort responded well and achieved
MRD-negative CR. Three patients with Down syndrome
and overt relapse all achieved MRD-negative CR/CRi, and
the fourth patient with Down syndrome had a decline in
MRD from 4 to 0.5%.
Response to InO was independent of number of prior
relapses, number of prior treatment attempts including
HSCT, CD19- and CD22-directed immunotherapy, or his-
tory of refractoriness to the immediate preceding treatment
attempt. Eighteen patients with overt relapse had undergone
one or more prior HSCT; all of these patients achieved CR/
CRi with InO. Of 11 patients with prior CD22-directed
therapy, seven responded well to InO (CR/CRi).
Post InO therapy and outcome
Twenty-one patients underwent HSCT after InO therapy.
The median time from last dose of InO to stem cell infusion
was 26 days (range 13–91 days). Two patients received
blinatumomab and one received CD19 CAR T-cell therapy
as a bridge to HSCT post InO for MRD positivity.
Thirty-one patients experienced the following ﬁrst
events: eight treatment failures, 12 relapses (includes 4 after
HSCT), and 11 deaths (ﬁve with disease, six in remission).
Median follow-up was 112.5 days in the 20 patients without
an event, and 137 days in the 27 patients who were alive at
last contact (for both, range 19–736 days). Over 75% of
patients were followed for at least 82 days. Sites of relapse
in the 12 patients who developed disease recurrence post
InO were marrow in ten and isolated extramedullary disease
in two patients (central nervous system (CNS) and an
extracranial mass in one patient, inﬁltration of ocular
muscle, kidney and pancreas in one patient). Overall, 18
(35%) patients were alive in CR and nine (18%) were alive
with evidence of disease. Seven patients (14%) died from
transplant-related toxicity while 17 (33%) expired from
progressive leukemia. The 12-month EFS and OS rates for
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the entire cohort were 23.4 ± 7.5% and 36.3 ± 9.3%
respectively (Fig. 1).
CD22 expression post InO
Comprehensive CD22 expression was evaluated in three
patients. Pre/post InO leukemia samples were available for
two patients, and only a post-InO sample following relapse
was available for one patient. In all three cases at the time of
relapse, leukemic blasts were noted to be either partial
CD22 positive, fully CD22 negative, or had diminution of
CD22 expression (Fig. 2). In one case, CD22 expression
increased with additional time post InO, but only partial
positivity was maintained.
Toxicities of InO
No patient died from toxicity during InO therapy. One or
more nonhematologic toxicities were reported in 34 patients
during all cycles. The majority of toxicities (79%) were
reported during cycle 1 and are listed in Table 2. Grade 3/4
hepatotoxicity was infrequent, and no patient developed
SOS while receiving InO. During the ﬁrst cycle of InO, one
patient developed grade 3 hyperbilirubinemia, while grade 3
ALT and AST elevations were seen in three (6%) and two
(4%) patients respectively. In subsequent cycles, only one
patient developed recurrent grade 1 AST and ALT elevation
and one additional patient developed grade 1 AST eleva-
tion. There was no evidence to suggest increased hepato-
toxicity with cumulative exposure to InO. Two (4%)
patients developed transient grade 3 InO-related infusion
reactions with hypotension in cycle 1 and one patient in
cycle 2. In this heavily pretreated patient population, febrile
neutropenia and infectious toxicities were reported in eight
(16%) and 15 (29%) patients respectively (cycle 1 data
only). Infectious toxicities included sepsis (N= 3), bacter-
emia (N= 2), invasive fungal infections (N= 2; both grade
3, one candidemia and one probable lung infection), gas-
trointestinal (N= 3), lung (N= 1), sinus (N= 1), and
unspeciﬁed (N= 3). Two patients developed bleeding
complications (gastrointestinal, epistaxis) while thrombo-
cytopenic. In addition, two patients developed CNS bleed-
ing in the setting of progressive CNS disease during cycle 2.
Interestingly bone pain was reported by four (8%) patients
in cycle 1 and an additional patient in cycle 2; however, it
was not possible to discern if pain was attributable to InO or
progressive disease.
Post-HSCT sinusoidal obstruction syndrome
Twenty-one patients underwent HSCT after achieving CR.
Eleven of 21 patients (52%) developed post-HSCT SOS:
four mild, two moderate and ﬁve severe, including two
events that were fatal. The overall rate of SOS in the entire
cohort of 51 patients was 22%. There was a trend to greater
risk of SOS in patients who had received one or more
HSCT prior to InO: 6/11 (55%) vs. 3/10 (30%) in patients
with no prior HSCT, and in patients whose conditioning
regimens contained busulfan or clofarabine (Table 3).
However, no other potential risk factors, including number
of doses of InO, time from InO to HSCT, or conditioning
with dual alkylator or total body irradiation were sig-
niﬁcantly associated with higher incidence of SOS.
Discussion
As in adults, weekly InO was highly effective in children
with relapsed/refractory ALL with a CR/CRi rate of 67%.
The majority of these responders (71%) attained MRD
negativity. Responses were seen in patients irrespective of
disease burden or number and type of prior therapies. We
did not identify any patient-speciﬁc or disease-related fac-
tors that predicted for effectiveness of InO. Encouraging
responses were noted in patients with high-risk features
Fig. 1 EFS (a) and OS (b). The 12-month EFS and OS rates for the
entire cohort of 51 patients were 23.4 ± 7.5% and 36.3 ± 9.3%,
respectively
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such as Ph-positive, Ph-like and hypodiploid ALL, as well
as in patients with Down syndrome. Forty percent of
patients were able to proceed to HSCT with curative intent.
Within the relatively short follow-up period, 12 patients
developed a subsequent relapse post InO. Though we only
quantiﬁed CD22 expression for three patients in this cohort,
one important escape mechanism at relapse may be mod-
ulation of the CD22 antigen expression on leukemic blasts,
analogous to antigen loss associated with CD19-directed
therapies such as blinatumomab and CD19-CAR T-cell
therapies [16, 17]. Similar analyses on a larger number of
patients will provide further insights into resistance to
CD22-directed therapy.
InO was generally tolerated well, even by patients who
were heavily pretreated. Infectious toxicity was lower than
what is typically reported with chemotherapy regimens for
patients with multiply relapsed ALL [18, 19]. Hyperbilir-
ubinemia and transaminitis were low-grade and manage-
able. Hematologic toxicity could not be assessed adequately
in this cohort of patients due to baseline cytopenias. In view
of fewer infectious and organ toxicities compared to
intensive cytotoxic chemotherapy, InO like other novel
immune-targeted therapies, is an attractive means to achieve
remission in a patient with relapsed/refractory disease to
allow for HSCT.
Whereas some adults developed SOS during InO ther-
apy, pediatric patients receiving InO only developed SOS
following HSCT. However, the incidence of SOS was high
in this pediatric cohort with an overall rate of 22, and 52%
in the HSCT setting, vs. 13 and 22% respectively reported
in adults in the phase III INO-VATE global trial [12].
Pediatric patients in this study may have had additional
independent risk factors for SOS compared to patients
enrolled on the adult phase II study wherein the incidence of
post-HSCT SOS was 23% [8]. As this was a compassionate
use study, all patients were heavily pretreated with multiple
intensive chemotherapy and immunotherapy regimens; 92%
of patients received InO for ≥3rd salvage, compared to 24%
CBA22DCnoisserpxe22DC
Patient 1 Pre-InO (A) 059%99>
031<%4)B(OnI-tsoP
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Patient 2 Pre-InO (D) 8202%99>
229%99>)E(OnI-tsoP
Patient 3 (F) Post-InO (population 1, CD22+) 89% 3973 
  Post-InO (population 2, CD22-) Negative <100 
ABC: antibody binding per cell 
Fig. 2 CD22 expression at
relapse post-InO. CD22
expression in two patients
evaluated pre- and post- InO and
in one patient post-InO. CD22 is
uniformly expressed on >99%
B-lymphoblastic leukemia cells
prior to InO (a, d); however,
CD22 expression is diminished
or absent (b, c, e) or absent in a
subset of lymphoblasts (f) after
InO
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of adult patients [8]. Similarly, 43% of pediatric patients
had undergone ≥1 HSCT prior to InO, vs. only 14% of adult
patients. The adult experience with gemtuzumab ozogami-
cin suggests higher risk of SOS if the agent is followed by
HSCT within 3 months [11]; however, this was not con-
ﬁrmed in a pediatric study [20]. The median time from last
dose of InO to HSCT was 6 weeks in the adult InO study,
and 3.7 weeks in this pediatric cohort; thus, it is not known
if the risk of SOS with InO can be attenuated by delaying
HSCT. We could not discern if higher pre-HSCT transa-
minase and bilirubin values were associated with a higher
risk of SOS as these data were not collected, but there was
no correlation of SOS to the occurrence of these toxicities
during InO therapy. The use of two alkylators and/or
busulfan in the conditioning regimen increased the risk of
SOS in adult patients. Due to the small number in the
pediatric cohort who underwent HSCT, we were unable to
identify signiﬁcant risk factors for SOS; however, there was
a trend of developing post-HSCT SOS when conditioning
included clofarabine and/or busulfan. Both patients with
fatal SOS had received clofarabine for conditioning, an
agent known to be associated with a high incidence of
hepatotoxicity and SOS [18]. In addition, the more frequent
use of myeloablative conditioning in pediatric patients
compared to reduced intensity conditioning in adult patients
may inﬂuence the incidence of post-HSCT SOS. The use of
ursodiol or deﬁbrotide for SOS prevention or treatment was
not ascertained in a uniform manner. The use of these
agents for prophylaxis may decrease the risk and severity of
SOS during post InO HSCT, and therefore patients who
undergo HSCT post InO are eligible for the ongoing study
of deﬁbrotide prophylaxis (NCT02851407). With improved
access to CAR T-cell therapies more pediatric patients
could potentially avoid a second HSCT and subsequent
SOS.
This study has several limitations. Since only approxi-
mately 50% of patients who received InO by the compas-
sionate use program as of the study cutoff date are included
in this study, the introduction of unintended reporting bias
could not be avoided. Additionally, it is a retrospective
study wherein all data were reported by individual institu-
tions that may have varied in the comprehensiveness of
toxicity reporting; thus, positive ﬁndings may be more
reliable than negative ﬁndings. However, we believe that
major toxicities and grading were accurately captured.
Unlike a prospective study with well-deﬁned eligibility
Table 2 Toxicities during cycle 1
Toxicity Grade 1–2 Grade 3a Grade 4 Unknown grade Total
ALT increase 6 (11.8%) 3 (5.9%) 9 (17.6%)
AST increase 8 (15.7%) 2 (3.9%) 10 (19.6%)
GGT increase 2 (3.9%) 1 (2.0%) 1 (2.0%) 4 (7.8%)
Hyperbilirubinemia 1 (2.0%) 1 (2.0%)
Fever 9 (17.6%) 9 (17.6%)
Febrile neutropenia 2 (3.9%) 6 (11.8%) 8 (15.7%)
Infection 4 (7.8%) 8 (15.7%) 2 (3.9%) 1 (2.0%) 15 (29.4%)
Bone pain 3 (5.9%) 1 (2.0%) 4 (7.8%)
Infusion reaction 2 (3.9%) 2 (3.9%)
Vomiting 2 (3.9%) 1 (2.0%) 3 (5.9%)
Diarrhea 1 (2.0%) 1 (2.0%) 2 (3.9%)
Tumor lysis syndrome 2 (3.9%) 2 (3.9%)
Bleeding 1 (2.0%) 1 (2.0%) 2 (3.9%)
Electrolyte disturbances 7 (13.7%) 3 (5.9%)b 10 (19.6%)
aAdditional grade 3 toxicities noted in one patient each: anorexia, hypertension, hypertriglyceridemia,
paroxysmal atrial tachycardia
bGrade 3 electrolyte disturbances: hypokalemia (2), hypocalcemia (1)
Table 3 Risk factors for post-transplant SOS
Risk factor SOS (N= 11) No SOS
(N= 10)
Median age in years (range) 12 (2–19) 12.5 (7–19)
Median doses of InO (range) 6 (3–12) 4.5 (3–6)
Median days from InO to HSCT
(range)
25 (13–91) 30 (13–89)
One or more HSCT prior to InO 6 (55%) 3 (30%)
Dual alkylator conditioning 6 (44%) 7 (54%)a
Busulfan containing conditioning 5 (45%) 1 (11%)a
Clofarabine containing
conditioning
3 (27%) 1 (11%)a
TBI conditioning 9 (82%) 6 (60%)a
aConditioning regimen was unknown for one patient
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criteria, the heterogeneity of the patient cohort with respect
to disease burden, performance status, comorbid conditions
and number and type of prior therapies may impact inter-
pretation of the results.
Despite these limitations, we show that InO is an effec-
tive and relatively safe agent for pediatric patients with
relapsed/refractory ALL. There are currently two pro-
spective pediatric phase II trials of InO for patients with
relapsed/refractory, one in the United States
(NCT02981628) and one in Europe (EudraCT 2016–
000227–71); the latter is planned in combination with
chemotherapy after the single agent phase. Data generated
from these studies will provide more comprehensive data on
the efﬁcacy and toxicities of InO as it is potentially moved
to frontline therapy. InO is a particularly attractive candi-
date for combination chemotherapy/immune-targeted ther-
apy in de novo ALL, as the majority of these patients will
not require HSCT, thus minimizing the risk of SOS which is
the principal toxicity of concern with this agent.
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